血小板糖肽Ⅱb/Ⅲa受体拮抗剂研究现状
赵秀丽,胡大一
摘要(Abstract)：
关键词(KeyWords)：
基金项目(Foundation):
作者(Author): 赵秀丽,胡大一
参考文献(References)：
- 1 EPIC INvestigators. Use of a monoclonal antithey directedagainst the platelet glycoprotein Ⅱb/Ⅲa receptors in highrisk coronary angioplasty. N Eng J Med, 1994, 330: 956-961.
- 2 Topol EJ,Califf RM, Weismann HF,et al. Randomized trialof coronary intervention with antithey against platelet Ⅱb/Ⅲa integrin for reduction of clinical restenosis:results at sixmontbs. Lancet, 1994, 343: 881 -886.
- 3 Bhattacharya S, Weisman HF, Morris KG, et al. Chimerization of monoclonal antithey 7E3 preserves the GP Ⅱb/,Ⅲareceptor blokade and platelet functional inhibiton of murine7E3. Clin Res, 1991, 39: 196A.
- 4 Simoos ML,de ther MJ, van den Brand MJBM,et al. Randondzed trial of GP Ⅱb/Ⅲa platelet receptor bloker in refractory unstable angina. Circulation. 1994, 89: 596-603.
- 5 Tcheng JE, Eilis SG, therge BS, et al. Pharmacodynamicsof chimeric glycoprotein Ⅱb/Ⅲa integrin antiplatelet antibody Fab 7E3 in high-risk cotonary angioplasty. Circulation, 1994, 90: 1757-1764.
- 6 Landau C, lange RA, Hillis LD. Percutaneous translundnalcoronary angioplasty. N Engl J Med, 1994, 330: 981-993.
- 7 Tcheng JE- Glycoprotein Ⅱb/Ⅲa receptor inhibitors:putting the EPIC, IMPACT Ⅱ RESroRE and EPILOGtrials into PersPective. Am J Cardiol, 1996, 78: 35-40.
- 8 FitzGerald GA. ffeyond aspirin: EPIC opens the door. Vessels, 1995, 1: 3-8.
- 9 Kleiman NS,Ohman EM,Califf RM,et al. Profound inhibition of platelet aggregation with monoclonal antithey to7E3 Fab after thrombolytic therapy. Results of the thromb0lysis and angioplasty in myocardial infarction (TAMI) 8pilot study. J Am Coll Cardiol, 1993, 22: 381-389.
- 10 Coller BS, Scudder LE, Beer J, et al. Monoclonal antibodiesto platelet to glycoprotein Ⅱb/Ⅲa as antithromhatic agents. Ann N Y Acad Sci, 1991,614: 193-213.
- 11 Aguirre F, Ferguson JJ, Califf RM- Clinical predictors ofbleeding complications in high risk angioplasty patients: results from the EPIC study group. Circulation, 1993, 88 (suppl Ⅰ):Ⅰ-252.
- 12 Farrell DH, Thiagarajan P, Chung DW, et al. Role of fibrinogen Q and Y chain sites in platelet aggregation. Proc NatlAcad Sci USA, 1992, 89: 10729-10732.
- 13 Gartner TK, Bennett JS. The tetrapeptide analogue of thecell attachment site of fibronectin platelets. J Biol Chem,1985, 260: 11891-11894.
- 14 Simpfendorfer C, Kottke-Marchant K, Toppl EJ- First experience with chronic platelet GP Ⅱb/Ⅲa receptorblokade: A pilot study of xemlofiban an orally active antagonist in unstable angina patients eligible for PTCA. J AmColl Cardiol, 1996, 27 (suppl A): 242A.
- 15 Weisenberger NH, Muller TH,Deichsel G, et al. Tolerabilltyand platelet fibrinogen receptor occupancy (FRO) after oraltreatment with BIBU 104 XX in healthy volunteers.Thromb Haemost, 1995, 73: 1315.
- 16 Ohman EM, Kleiman NS,Gacioch G, et al. Combined accelerated tissue-plasminogen activatorand platelet glycoproteinⅡb/ Ⅲa Integrin receptor blokade with integrilin in acutemyocardial inaarction. Circufation, 1997, 95: 847-854.